Nervonik Raises $52.5M Series B to Advance Wireless Peripheral Nerve Stimulation for Chronic Pain
In Los Angeles, a clinical-stage medtech company just turned up the volume on a signal most systems still struggle to hear. Nervonik locked in $52.5M in Series B funding, led by Amzak Health with Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital in the mix. Capital is flowing, but this isn’t about cash for the sake of headlines. It is about precision entering a category that has lived with blunt instruments for far too long.
Built out of UCLA research, Aydin Babakhani, CEO, is pushing a different philosophy into the clinic. Nervonik’s wirelessly powered peripheral nerve stimulation system is designed to interact with the body, not override it. Chronic pain, especially of peripheral nerve origin, doesn’t behave like a binary problem, and treating it like one has always been the flaw. This approach leans into variability instead of ignoring it.
Inside the company, the bench is deep and deliberate. Chief Scientific Officer Jeff Kramer brings experience from Medtronic and Abbott into the science layer, while COO Tim Corvi translates that into execution shaped by prior roles at Acutus and Medtronic Ablation Frontiers. General Counsel Andrew Filler and Director of Quality and Regulatory Affairs Scott Herr anchor the regulatory path, while Chief Clinical Advisor Timothy Deer and a network of clinical advisors including Hemant Kalia, Ramo Naidu, Melissa Murphy, and Alaa Abd-Elsayed connect the technology to real patient environments where outcomes actually matter.
The company has already completed its first-in-human clinical trial, which in this space is where theory meets consequence. Data replaces assumption. Progress becomes measurable. That step, layered on top of a $13M Series A in March 2025 and an earlier $4.4M in seed capital, brings total funding to roughly $69.9M. Each round feels less like a leap and more like a calculated step forward, backed by investors who understand how long real medtech breakthroughs actually take.
The system integrates sensing with stimulation, allowing therapy to adjust rather than repeat. Not guesswork, not static output. Responsive, adaptive, built for variability. In a market where more than 50M people in the U.S. live with chronic pain, that level of responsiveness is not a feature. It is the difference between temporary relief and something that actually holds.
Execution stands out here. Clinical validation before scale. Engineering depth before market noise. Many try to accelerate that sequence and end up with visibility instead of viability. Nervonik kept the order intact and let the results speak in their own frequency. Medtech has a habit of rewarding volume over clarity. This time, clarity is getting funded. And Nervonik is moving with the kind of signal that does not need amplification to be noticed.
